NuVasive develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company was founded in 1997 and is based in San Diego, California.
NUVA Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Nuvasive Inc. To summarize, we found that Nuvasive Inc ranked in the 34th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Nuvasive Inc ended up being:
The company's compound free cash flow growth rate over the past 5.56 years comes in at 0.12%; that's greater than 52.47% of US stocks we're applying DCF forecasting to.
77% of the company's capital comes from equity, which is greater than 61.64% of stocks in our cash flow based forecasting set.
The weighted average cost of capital for the company is 7. This value is greater than only 23.58% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as NUVA, try ENTA, BHC, NVS, USPH, and IQV.